相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
Kosuke Ebina et al.
MODERN RHEUMATOLOGY (2021)
RANKL as a target for the treatment of osteoporosis
Toshio Matsumoto et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2021)
Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial
Akimitsu Miyauchi et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2021)
Over half of seniors who start oral bisphosphonate therapy are exposed for 3 or more years: novel rolling window approach and patterns of use
K. N. Hayes et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
E. Soreskog et al.
OSTEOPOROSIS INTERNATIONAL (2021)
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Athanasios D. Anastasilakis et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study
J. Everts-Graber et al.
BONE (2021)
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Felicia Cosman et al.
CURRENT OSTEOPOROSIS REPORTS (2021)
The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
Yilin Zhu et al.
JOURNAL OF ORTHOPAEDIC TRANSLATION (2020)
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial
Junichi Takada et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2020)
Bone Mineral Density After Transitioning From Denosumab to Alendronate
David Kendler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
Emil H. Schemitsch et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2020)
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
Judith Everts-Graber et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study
E. M. C. Lau et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Masaki Kobayashi et al.
BMC WOMENS HEALTH (2020)
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study
Houchen Lyu et al.
ANNALS OF INTERNAL MEDICINE (2020)
Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
Hideomi Kondo et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2020)
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis
Polyzois Makras et al.
BONE (2020)
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Osteoporosis in Older Adults
Catherine Bree Johnston et al.
MEDICAL CLINICS OF NORTH AMERICA (2020)
Effect of risedronate on bone loss at discontinuation of denosumab
Michel Laroche et al.
BONE REPORTS (2020)
Incidence of venous thromboembolism among postmenopausal women prescribed ospemifene, selective estrogen receptor modulators for noncancer indications, or untreated vulvar and vaginal atrophy
Beth L. Nordstrom et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2020)
The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study
Chan Ho Park et al.
BMC MUSCULOSKELETAL DISORDERS (2020)
Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
Kosuke Ebina et al.
BONE (2020)
Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol
Tsuyoshi Asano et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2019)
The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients
Masayuki Miyagi et al.
JOURNAL OF ORTHOPAEDIC SCIENCE (2019)
Clinical Update on Osteoporosis
Angelina Anthamatten et al.
JOURNAL OF MIDWIFERY & WOMENS HEALTH (2019)
Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis
Fei Yuan et al.
INTERNATIONAL JOURNAL OF SURGERY (2019)
Bazedoxifene for the treatment of osteoporosis
Maria P. Yavropoulou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use
Houchen Lyu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Increased bone mineral density for 1year of romosozumab, vs placebo, followed by 2years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
Akimitsu Miyauchi et al.
ARCHIVES OF OSTEOPOROSIS (2019)
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials
Adrian Hernandez et al.
MATURITAS (2019)
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Anabolic Therapies in Osteoporosis and Bone Regeneration
Gabriele Russow et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Treating osteoporosis to prevent fractures: current concepts and future developments
Mattias Lorentzon
JOURNAL OF INTERNAL MEDICINE (2019)
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment
Nuria Guanabens et al.
ENDOCRINE (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
Albrecht Werner Popp et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Long-term treatment strategies for postmenopausal osteoporosis
Felicia Cosman
CURRENT OPINION IN RHEUMATOLOGY (2018)
Denosumab: A Review in Postmenopausal Osteoporosis
Emma D. Deeks
DRUGS & AGING (2018)
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density
K. E. Naylor et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab
Noam Yarom et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2018)
Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis
Tomoko Usui et al.
ARCHIVES OF OSTEOPOROSIS (2018)
Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial
Rui Niimi et al.
JBMR PLUS (2018)
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Benjamin Z. Leder
JBMR PLUS (2018)
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
Kosuke Ebina et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2017)
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study
Joy N. Tsai et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial
Joy N. Tsai et al.
JOURNAL OF CLINICAL DENSITOMETRY (2017)
Case-aced Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ
Aliya A. Khan et al.
JOURNAL OF CLINICAL DENSITOMETRY (2017)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
Panagiotis Anagnostis et al.
MATURITAS (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
T. Lehmann et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Observations following discontinuation of long-term denosumab therapy
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2017)
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study
C. Reyes et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis
Elisa Martin-Merino et al.
ARCHIVES OF OSTEOPOROSIS (2017)
Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy
Benjamin Z. Leder
CURRENT OSTEOPOROSIS REPORTS (2017)
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Elena Tsourdi et al.
BONE (2017)
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Ian R. Reid et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study
Hideaki Ishibashi et al.
BONE (2017)
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)
Benjamin Z. Leder et al.
BONE (2017)
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials
Ana Boquete-Castro et al.
CLINICAL ORAL IMPLANTS RESEARCH (2016)
Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
P. D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
Denosumab in treatment-naive and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers
Athanasios D. Anastasilakis et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014)
J. Gonzalez-Macias et al.
REVISTA CLINICA ESPANOLA (2015)
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial
Toshitsugu Sugimoto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Systemic Administration of Sclerostin Antibody Enhances Bone Repair in a Critical-Sized Femoral Defect in a Rat Model
Mandeep S. Virk et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2013)
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Endogenous tissue engineering: PTH therapy for skeletal repair
Masahiko Takahata et al.
CELL AND TISSUE RESEARCH (2012)
Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data
David W. Dempster et al.
CLINICAL THERAPEUTICS (2012)
Denosumab: mechanism of action and clinical outcomes
D. A. Hanley et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
N. Freemantle et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Teriparatide Accelerates Lumbar Posterolateral Fusion in Women With Postmenopausal Osteoporosis Prospective Study
Seiji Ohtori et al.
SPINE (2012)
Bisphosphonates: The first 40 years
R. Graham G. Russell
BONE (2011)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-Blind Study of 102 Postmenopausal Women With Distal Radial Fractures
Per Aspenberg et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
David L. Kendler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Atrophyc humeral shaft nonunion treated with teriparatide (rh PTH 1-34): A case report
Ángel Oteo-Álvaro et al.
JOURNAL OF SHOULDER AND ELBOW SURGERY (2010)
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Skeletal effects of raloxifene after 8 years: Results from the Continuing Outcomes Relevant to Evista (CORE) study
ES Siris et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy -: A randomized controlled trial
BH Ascott-Evans et al.
ARCHIVES OF INTERNAL MEDICINE (2003)
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial
SL Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2002)
分享论文
